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Summary.-The effect of simultaneous whole-body heat (45 min 41°C) on cyclo-
phosphamide (CTX) and BCNU toxicity to normal mouse marrow stem cells and to
the RIF-1 tumour in C3H/He mice has been studied. Marrow stem-cell survival was
assayed by the spleen-colony technique at both 2 and 24 h after treatment, and also by
following peripheral WBC count during the weeks after treatment. Heat potentiation
of CTX toxicity to marrow stem cells was similar at both times and 24 h after treat-
ment heat was dose-modifying with a DMF of 2-0. The heat potentiation of BCNU
toxicity to stem cells was much greater at 24 h than at 2 h, and at 24 h had a DMF
of 2-1. Peripheral WBC counts supported the results from 24 h assay for both drugs.
RIF-1 tumour response was assayed by clonogenic cell survival measured 24 h after
treatment, and by growth delay. For clonogenic tumour-cell survival after CTX,
heated and unheated curves were parallel at doses above 75 mg/kg, yielding DMFs
varying between 1-9 and 1-4 according to dose. DMFs for BCNU were also dose-
dependent, lying between 2.0 and 1 6, the RIF-1 tumour being much less sensitive to
BCNU than to CTX. Growth-delay data agreed with clonogenic cell survival. Thera-
peutic ratios for the combination of heat with CTX or BCNU fell in the range 0-91-
0-69, according to dose, i.e. no gain or even therapeutic loss under the conditions of
this study.
THE POTENTIATING EFFECT of heat on
the in vivo tumoricidal activity of a
number of cytotoxic drugs including CTX,
BCNU, Bleomycin and Adriamycin is now
well established (Overgaard, 1976; Hahn,
1978; Twentyman et al., 1978; Marmor,
1979). So far there have been few normal-
tissue studies on such combinations,
though we have previously reported work
on skin (Honess & Bleehen, 1980). How-
ever, marrow may be a more critical
normal tissue, in that a limiting toxicity
of two of the drugs mentioned above
(CTX and BCNU) is to the marrow when
each is administered clinically as a single
agent. Sabio et al. (1981) have reported in
mice that hyperthermia alone (41.5-
44 5°C) decreases the number of stem
cells available for proliferation and also
that the proliferative potential of surviv-
ing cells is decreased. Symonds etal. (1981),
studying the effects of in vitro hyper-
thermia (41-44°C) on stem cell and L1210
leukaemia cell survival, report similar
slopes for survival curves for both cell
types, but a greater susceptibility of
L1210 cells to heat when in the presence
of normal marrow. Chrisman & Baum-
gartner (1980) have demonstrated highly
significant effects ofheat, CTX (40 mg/kg)
and of the interaction of heat and CTX on
the incidence of micronucleated poly-
chromatic erythrocytes in the marrow of
ICR mice. Rose et al. (1979) have investi-
gated the effect of whole-body hyper-
thermia as an adjunct to a variety of
chemotherapeutic agents in several mouse
tumour systems, using death as the end-
point, and failed to demonstrate any
reproductible or stubstantial enhancementTHERAPEUTICRATIO FOR HYPERTHERM1IA AND DRUGS
of the chemotherapy. In the work des-
cribed here we have studied the effects of
the combination of heat with CTX or
BCNU on the femoral marrow of normal
C3H/He mice, using the spleen-colony
assay of Till & MeCCulloch (1961) as a
measure of marrow stem-cell survival
(CFU-S) and also peripheral WtBC count
as a measure of the end product of any
stem-cell damage. WVe have also studied
the effects of the same combinations oIn
the RIF-1 tumour in the same mice under
the same conditions, assaying tumour
response by clonogenic cell survival and
growth delay, in order to compare normal-
tissue damage with tumour response and
hence to estimate therapeutic ratios for
the combinations.
Whole-body hyperthermia was chosen
for two reasons. Firstly, it is extremely
difficult to heat uniformly a well-vascu-
larized organ such as the femoral marroN
by local heating, because of the efficiency
of the blood cooling, and it is impossible
to avoid temperature gradients within the
femur. The efficiency of local cooling
around blood vessels in heated gut has
been clearly demonstrated by Hume et al.
(1979) and similar effects can be expected
in marrow. Also, the problem of tempera-
ture monitoring within the femur without
disrupting blood flow is one we have not
solved, and the work of Hume et al. (1979)
demonstrates that there can be substantial
temperature differentials over very small
distances (- 1°C/mm) adjacent to blood
vessels. However, all these problems are
circumvented by raising the temperature
of the whole mouse, so that no local
cooling by the circulation can occur. We
have assumed that the femoral tempera-
ture very closely approaches the core
temperature of the animal, which can be
easily monitored with a rectal probe.
Tumour temperatures were essentially
identical to core temperature. Secondly,
it has been suggested that a modest level
of whole-body hyperthermia might be
used clinically to facilitate attaining
suitable temperatures for effective local
hvperthermia, by reducing the efficiency
of blood cooliing. Thus nmodest whole-body
hyperthermia is a clinically relevant
technique. The temperature used in this
study (41TC) is comparable with that
which would be used clinically.
Till and McCulloch's spleen colony
assayis a convenient and well-tried method
of assaying marrow stem-cell damage. I't
is difficult, however, to decide on the most
relevant time after treatment to perform
the assay. In work with cytotoxic drugs,
W1asserman et al. (1981), among others,
assay,ed 2 h after treatment; Van Putten
et al. (1972) assayed 16 h after treatment
and Hellman & Grate (1971) assayed at
:3 and 24 h after treatment. There are
various factors which cani affect the
ineasurement of marrow stem-cell survival
after cytotoxic treatment- some would
indicate an early assay to avoid artefacts
and others a late assay. These factors are
that surviving stem cells may: (a) start
to proliferate, (b) migrate away from the
marrow, and (c) differentiate, thereby
losing their colony-forming ability. These
3 factors all indicate that an early assay
wouild incur the fewest artefacts. However,
other factors are that: (d) there may be
residual drug present at an early assay,
(e) recovery from potentially lethal dam-
age may occur, and (f) there may be
"residual heat damage" similar to that
shown in tumours, whereby cells left in a
heated environment continue to lose
viability for up to - 24 h after treatment.
These last 3 factors indicate that a late
assay would be desirable. In this work we
have therefore assayed at both 2 and 24 h
after drug treatment.
MATERIALS ANI) MlETHODS
Mlice
Female C3H/He mice wvere obtained froml
Olac (Southern) Limited (Bicester) and were
used as marrow recipients at 12-16 wseeks of
age. For other purposes mice wsere treated at
20-30 g in weiglht.
D)ruys
Cyclophosphlamide (CTX. WNB Pharnia-
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ceuticals) was obtained as powder for injec-
tion, containing the equivalent of 200 mg
anhydrous CTX with sodium chloride.
1,3 - Bis - (2 - chloroethyl - 1 - nitrosourea)
(BCNU) was kindly supplied by the Drug
Development Branch, Developmental Thera-
peutics Program, Division of Cancer Treat-
ment, National Cancer Institute (Bethesda,
Md.) in 100mg vials. BCNU was dissolved in
absolute ethanol immediately before dilution
(at least 1 in 20) for use.
Both drugs were diluted in Hanks' bal-
anced salt solution and injected i.p. When
combined with heat treatment, drugs were
always given at the start of heating.
Hyperthermia
Unanaesthetized, unrestrained mice were
given whole-body hyperthermia by enclosing
them in a wire-mesh cage (allowing maximum
ventilation) placed in an incubator at 44°C.
The cage was situated under a fan which
ensured brisk air circulation, and fresh air
was pumped into the incubator at a rate of
10 1/min, which allowed a complete change of
air every 15 min. It was found that these two
features markedly reduced animals, suscepti-
bility to heat stroke at this treatment
temperature. A maximum of 8 mice were
treated per session.
Independent measurements of rectal tem-
perature in mice restrained sufficiently to
allow a rectal probe to be kept in place,
while still allowing free sweating, showed that
the rectal temperature reached 41 + 0 2°C
within 5-10 min of the start of heating, and
was maintained throughout treatment. Intra-
tumour measurements in these animals
showed that the temperature in the centre of
the tumour was always closely associated with
the rectal temperature and within + 0 2°C of
it. The temperature at the very surface of
the tumour, however, tended tobehigher than
the rectal temperature, and approached that
of the skin of the animal, which was at the
higher incubator temperature.
A standard heat treatment of 45 min at
41°C was used in all the experiments reported
below, which entailed 50 min total time in
the incubator. A BAT-8 digital thermometer
(Bailey Instruments Inc.) was used to
monitor rectal and intratumour tempera-
tures and incubator air temperatures, the
air probe being carefully shielded from the
fan.
Normal-tissue end-points
Marrow stem-cell survival.-This was meas-
ured by the spleen colony (CFU-S) assay of
Till & McCulloch (1961). Groups of 10-15
recipient mice were lethally irradiated with
8-25 Gy of 60Co y-rays the evening before
receiving i.v. a marrow-cell suspension, pre-
pared from at least 2 control or treated donor
mice by killing the animal by cervical dis-
location, dissecting out the femurs, cutting
off the distal end of the femur with scissors
and making a hole in the proximal end be-
tween the condyles with a 25-gauge needle
and flushing out the contents into a glass
universal container with 1 ml of HBSS. The
femur was flushed through twice more with
1 ml of HBSS and this 3 ml suspension was
then syringed repeatedly to obtain a single-
cell suspension which was kept on ice until
injection into the recipients. It was found
that this method ofharvesting yielded 99% +
of the total obtained by many subsequent
flushings. A sample of the suspension was
then diluted 1:1 or more (according to cell
count) with 2% glacial acetic acid in distilled
water. This lysed the red blood cells and
allowed nucleated cells to be counted in a
haemacytometer. Appropriate dilutions of
marrow-cell suspension were made in HBSS;
so that each recipient mouse received 0-2 ml
given i.v. into the tail vein. Injections were
performed without anaesthaesia, and were
facilitated by dipping the tail in hot water
for a few seconds to dilate the vein before
injection, then in ice water afterwards to
encourage vasoconstriction and reduce the
likelihood ofbleeding.
Marrow recipients were killed 7-8 days
after i.v. injection and the spleens were
removed and fixed in Bouin's fluid, which
allowed the colonies on the surface of the
spleen to be clearly seen as yellow nodules
against a dark background. Colonies were
counted under a low-power stereomicroscope.
In this system it was found that for control,
untreated marrow, an inoculum of 105
nucleated cells produced 10-15 colonies per
spleen. It was shown that the number of
colonies depended linearly on the number of
cells injected, up to a colony count of 25-30.
Where there were 30+colonies it was impos-
sible to make an accurate count because of
crowding. Cell inocula were therefore adjusted
to give colony counts of 5-20 per spleen. The
rate of occurrence of endogenous spleen
colonies in irradiated animals was - 2/15
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spleen. and the rate of radiation death of
recipient mice before Day 7 was - 10%, but
varied between latclhes of animals.
Marrow stem-cell assays were carried out
at 2 and 24 h after the start of treatment (see
above). For 2 h assays, surviving fractions
are expressed in terms of spleen colonies per
marrowr cells injected, but for 24 h assays,
surviving fractions are expressed in terms of
spleen colonies per femur. This is because of
the drop in nucleated cell yield per femur
during the 24 h after drug treatment (see
Results). At 2 h the cell yield is indistinguish-
able from tlhat of the controls, so surviving
fractions are the same, expressed in either
manner.
Drug doses Awere selected to give a drop in
survival over one decade in unheated animals.
Peripheral WBC counts.-Groups of 8-10
mice were treated and blood samples were
taken on Days 3, 5, 7, 10, etc.. after treat-
ment. Ten ,ul of blood was taken from the
tail. into a heparinized capillary tube, and
diluted in 20 ml of Isoton (Coulter Electron-
ics Ltd). Heparinization wi-asnecessary because
of a tendency for the blood of heated mice to
clot very rapidly 3-5 days after treatment.
Red blood cells w-ere then lysed with Zaponin
(Coulter Electronics Ltd) and white cells were
counted in a Coulter Counter Model ZBI.
Arithmetic means wA-ere taken for each group.
and results were expressed as a percentage
of the control counts on that day. This was
because of the usual slight rise in VVBC
counts in control mice as a result of repeated
bleedings.
Drug doses were chosen to matclh the stem-
cell survival experiments -where possible, but
only lower doses of BCNU were compatible
with survival for the length ofthe experiment.
Tuwour
The tumour used in this, work -was the
RIF-I tumour wNhich has been previously
described by Twentyman et al. (1980). It was
grown i.m. in the leg by injection of 105 cells
from culture. Animals wN-ith tumour,s were
treated when the tumours reached a size of
300-600 mm3, usually Day 9-10 after inocula-
tion. tumour volume being estimated from a
calibration curve of tumour weight (propor-
tional to tumour volume) as a function of
the product of two mutually perpendicular
leg diameters (TwNentyman et al., 1979). These
leg diameters wvere measured with a specially
imiade Perspex gauge. Tumour response w-as
measured bv twN-o assays:
Clonogenic tumour-cell survival.-Tumiours
were excised 24 h after treatment, this being
the earliest time at wAhich most or all of the
recovery from potentially lethal damage
(PLD) is thought to be complete (Tw-entyman,
1977, 1979: Begg. 1980) yet it allows rela-
tively little time for proliferation of surviving
cells. Tumours wNere minced finely with
scissors and disaggregated by 45 min stirred
incubation in 1 mg/ml neutral protease
(Sigma) in complete Eagle's minimal essential
medium (MEM) supplemented with 20,O'
newborn calf serum, as described by Twenty-
man & Yuhas (1980). The resulting single-cell
suspension wNas counted wNith a haema-
cytometer, appropriate dilutions were made,
and cells Nere plated in 90 mm Petri dishes
in complete medium, as above. Dishes were
incubated for 12-13 days in a gassing incuba-
toir and then the colonies w-ere fixed,
stained and counted. The plating efficiencv
(PE) for control tumours w%as 35-5000. and
surviving fractions w%ere calculated from the
PE.
Drug doses wNere selected either to mnatch
the marrow' survival experiments, or up to a
dose calculated to give a clonogenic cell
survival within the lower limit of assay,
whichever was greater.
Tumour growth delay. Groups of 10
mice were used for each treatment and
tumours wAere then measured twice weekly.
Growth of eachi tumour was plotted, and the
time taken for each to reachi 4 x the mean
treatment volume wa-s recorded. Arithmetic
means for each group were calculated, and
comparison with the control group allowed
an estimate of the growNth delay due to each
treatment.
Drug doses were chosen to match the
marrowA-survival experiments as far as pos-
sible.
RESULTS
.Normal tissue
CFU-S. The drop in yield ofnucleated
cells per femur 24 h after drug treatment
is shown in Fig. 1. For CTX, the drop
appeared to be dose-dependent, with a
300o yield at 200 mg/kg in unheated
animals, heated femur yields being con-
sistently lower. For BCNU, the unheated
vield was about 5000 over the range of
2392). J. HON ESS AND) N. M1. BLEEHEN
0
i0d
3D
0
0
0
0
0
0 50 100 150
mg/kg CTX
200
r
* *
0
0 0
IF
0
t
0
0
loIl
0 30 60
mg/kg BCNU
FIC:. 1.-Nucleate(d cells peIr femur' 24 It after clrug treatment. *, unhleate(d animnals; 0, hleated
animals. Heat treatment was 45 mmil at 41'C. Each point showvs the mean for-2-6 mi(e.
doses, again with yields fromi heated
animals tending to be lower. Heat alone
had no effect on cell yield at 24 h.
Dose-response curves obtained from
unheated animals, both 2 and 24 h after
CTX and BCNU, are shown in Fig. 2.
Parameters describing these curves are
given in Table I. The shoulder evident on
the CTX curve at 2 h is eliminated by 24 h,
and the slopes of the exponential parts are
essentially the same. The BCNU curves
are virtually identical at both assay times.
The effect of heat (45 min at 41°C) on
these responses are shown in Fig. 3, and
the parameters for these curves are also
given in Table I. For CTX heat potentiates
stem-cell damage at 2 h at doses only in
excess of 100 mg/kg but when damage is
assayed at 24 h, potentiation is evident
at all drug doses. Again there is no evi-
dence for a difference in slope in the
exponential parts of the curves for
heated animals. For BCNU heat poten-
tiation of stem-cell killing is detected
at both assay times, but at 2 h this is
just a slight shift in the curve, with no
significant change in slope, whilst at 24 h
the effect is much more marked and there
is a change in slope comparable to that
seen for CTX at 24 h. Comparing slopes
* I)efined as:
foi heated and uinheated respionse curves
assayed at 24 h gives a Dose Modifying
Factor (DMF)* of 2-0 for CTX and 2 1
for BCNU.
Peripheral iVBC counts. Results of
two representative white-cell-count experi-
ments are shown in Fig. 4. Separate panels
show results for 200 and 100 mg/kg of
CTX, respectively, in Expt I and for
30 mg/kg BCNU in Expt 2. Heat alone
did not cause a major deviation fronm the
control count at any time point in these
or similar experiments. Both cytotoxic
agents caused a drop in WBC count, with
a nadir at Day 3. At 200 mg/kg CTX the
effect of heat and drug was to decrease
the nadir only slightly, but to maintain it
until at least Day 5 and to delav recovery
to normal levels by about 2 days. At
100 mg/kg the nadir was again only slightly
depressed by the addition of heat, and the
effect was almost to eliminate the Day 5
overshoot seen with CTX alone. The large
error bars on Day 5 drug-treated points
are because the recovery of WBC counts
of mice in each group was not well
synchronized. These resuilts would seem
to support the stem-cell survival data, in
illustrating the heat potentiation of drug
damage during the week after treatment.
D)ose of drlug to polduce a givein effect in control mi(,(
D)ose of cdrug to produtice the same effect in heated mice
17
10
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FIG. 2.-Marrow stem-cell survival of unheated animals following CTX and BCNUT. Assays were
carried out 2 and 24 h after treatment. Each point represents the mean of 7-14 spleens. Lines
fitted by least-squares regression.
TABLE I.-Parameters describing stem-cell survival dose-response curves for unheated
and heated animals treated with CTX or BCNU
Unheated
Slope + 2 s.e. Do
(kg/mg) (mg/kg)
0-011+0-006 90-9
0-013+0-002 76-9
0-045+0-015 22-2
0-041+0-006 24-4
They particularly substantiate the 24h
assay data, in that there is evidence for
a potentiating effect of heat on drug
damage at 100 mg/kg.
Heated
Slope + 2 s.e. Do
(kg/mg) (mg/kg)
0-033+0-009 30-3
0-026+0-003 38-5
0-052+0-006 19-2
0-085+0-010 11-8
At 30 mg/kg BCNU, heat alone only
slightly depressed the Day 3 nadir, but
again delayed the recovery to normal
levels by about 2 days, as with 200 mg/kg
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FIG. 4. Changes witlh time
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(45 min at 41°C) ( )
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an(l is expressed as a pereenta
couint on the same (lay. Errc
+ 2 s.e.
CTX. However, the nadir vi
case maintained, perhaps
reached only 35"h, co
- 12% for 200 mg/kg CT
This result again corroborate
survival assay measured at 24 h, in that
at 30 mg/kg BCNU with heat, a delay in
recovery to normal W171BC levels, comFar-
able with that with 100 mg/kg CTX and
heat was obtained. It will be noted that
the 24h stem-cell assay shows about the
_.;Z--- same amount of killing by 30 mg/kg
\' BCNU and 100 mg/kg CTX, and also
about the same degree ofheat potentiation
of this damage. It was not possible to get
WrBC counts for BCNU at 60 mg/kg to
12 i4 16 i8 compare with CTX at 200 mg/kg, because
of the toxicity of BCNU, particularly in
combination with heat.
rx
Turnour response
Clonogenictumour-cellsurvival. Results
of two representative experiments are
shown in Fig. 5. Parameters describing
the exponential parts of the curves are
given in Table II. Heat alone had no
effect on tumour-cell survival. The RIF-]
tumour is sensitive to CTX, and cell
killing is potentiated by heat (Fig. 5).
12 1i4 16 i However, the effect is to shift the curve
downwards without altering its slope
at doses above 75 mg/kg with heat. The
DMF is thus dose-dependent, being at a
maximunm of 1-9 at 125 mg/kg, and
gradually decreasing as the curves con-
tinue parallel. At 150 mg/kg the DMF is
1P6 and at 200 mg/kg is 1 4 (by extra-
polation). Data from other experiments
(not shown) indicated that the unheated
curve continues straight while the heated
one disappears below the limit of reliable
12 assay.
In contrast, the RIF- tumour is
in periplieral resistant to BCNU, as shown in Fig. 5,
itlb lheat alone and clonogenic cell killing is only slightly
(irug alone increased by heat. Again, the effects
7-10 animals appears to be to shift the curve down-
uge of control wards at doses up to 45 mg/kg, but with
wbar-s show greater potentiation at 60 mg/kg. These
data yield DMFs varying from 2-0 for
vas not in this 30 mg/kg to 1P6 for 60 mg/kg (Table IV).
s because it Growth delay. Results of a tumour
mpared with growth-delay experiment are given in
X with heat. Table III. It can be seen that again heat
Is the stem-cell alone has no effect on tumour growth.
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FIG 5. Clonogenic tumour cell survival after- CTX or BCNU. 0, unheatedI animals; 0, heate(d
animals. Heat treatment was 45 min at 41°C. Eachi point represents a tumour from I animal.
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TABLE II. Parameters describing exponential parts of tumour-cell survival dose-response
curvesfor unheated and heated animals treated with CTX or BCN ('
Unnheated
Slope + 2 s.e.
Drug (kg/mg)
CTX 0*062 +0006
BCNU 0*028+0(006
Do
(mg/kg)
16,1
:35 7
Heat, however, substantially increases the
growth delay caused by both 150 and
100 mg/kg CTX; the growth delay caused
by 150 mg/kg CTX in unheated animals
being the same as that caused by 100 mg/
kg CTX in heated animals, which gives a
DMF at 150 mg/kg of I 5. This agrees
well with the value of 1-6 at 150 mg/kg
obtained from the clonogenic cell-survival
assay.
RIF-1 is again seen to be refractory to
BCNU treatment at the doses of 4.5 and
Heated
Slope + 2 s.e. Do
(kg/mg) (mg/kg)
0( 059+0 017 169-9
(-041+0-010 24 4
30 mg/kg. Although slightly longer growth
delays are seen in heated groups, the
differences are not significant at the 50°
level.
Comparison of DMF values for normal
and tumour tissues in these mice using
the combination of heat with CTX or
BCNU, can now be made to estimate a
therapeutic ratio (TR) which mav be
defined as:
DMF for tumour
DMF for normal tissueTHERAPEUTIC RATIO FOR HYPERTHERMIA AND DRUGS
TABLE III.-Tumour response of unheated 'and heated animals
BUNU, assayed by growvth delay
Treatment
Control
Heat alone
150 mg/kg CTX
Unheated
Heated
100 mg/kg CTX
Unheated
Heated
45 mg/kg BCNU
Unheated
Heated
30 mg/kg BCNU
Unheated
Heated
* 3/10 died earlier.
Time to reach
4 x treatment
volume + 2 s.e.
(days)
4-8+ 0-5
5-1+0-3
19-8+ 1 9
27 - 0+ 2 - 4
13-3+ 11
20 -1+ 1* 7
6-0+0-7
8 - 6 + 2 6
5-6+0-8
6.8+0 9
TABLE IV.-Effect of heat on tumour and
marrow stem-cell survival at varying
doses of CTX and BCATU, assayed 24 h
after treatment
Dose
Drug (mg/,g) DMFtumOur; DMFmnarrow
CTX 75 1 6 2 0
125 1 9 2 0
150 1 6 2 0
200 1 4 2 0
BCNU 30 2 0 2 1
45 1 7 2 1
60 1 6 2-1
*TR < 1 implies therapeutic disadvantage.
TR*
0 78
0-91
0-81
0 69
0 97
0-81
0 77
(i.e. TR > 1I0 indicates a therapeutic
advantage and TR < 1G0 indicates a thera-
peutic disadvantage). Values obtained by
comparing DMFs obtained from the stem-
cell survival data with those from clono-
genic tumour-cell survival are presented in
Table IV. For CTX the TR varies with
dose, and it can be seen that the data
indicate that there is no therapeutic gain
from the combination of CTX with heat
at 125 mg/kg, and at other doses there is
a therapeutic loss. For BCNU a similar
range of values is obtained, indicating no
gain at 30 mg/kg and progressively greater
therapeutic loss at doses up to 60 mg/kg.
DISCUSSION
The elimination of the shoulder seen on
17
treated with CTX or
Growth delay
+ 2 s.e.
(days) n
10
0*3+0-6 10
15-0+2-0 11
22-2+2-5 7*
8-5+ 1-2 10
15-3+1-7 10
1-2+0-9 10
3-8+2-6 7*
0-8+0 9 10
2-0+ 1 0 10
the 2h stem-cell dose-response curve for
unheated CTX-treated animals 24 h after
treatment is in accordance with the
observations of Hellman & Grate (1971),
who assayed at 3 and 24 h after treatment
in C3H/Hej mice. The effect of combining
CTX with heat appears similar at both
early and late assays, in that the shoulder
on the 2h dose-response curve is main-
tained in heated animals (Fig. 3) and the
slopes of the exponential parts of the 2h
response curves do not differ from the
slopes of the corresponding 24h curves
(Table I). At 200 mg/kg there is about the
same heat potentiation of damage (one
decade) at both assay times.
For BCNU, the 2h stem-cell data for
unheated animals presented in this paper
agree closely with those of Wasserman
et al. (1981) who quote a Doof 19 mg/kg,
compared with our value of 22*2 mg/kg.
Our data for both 2 and 24 h also agree
with those of Van Putten et al. (1972) for
16 h after treatment with i.p. BCNU, but
they also report a much steeper dose-
response curve after s.c. administered
drug. The s.c. route is obviously unsuitable
for use in conjunction with an early assay,
so all our observations were carried out
using i.p. administration.
Despite the great similarity of the 2
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and 24 h dose-response curves for un-
heated animals treated with BCNU (Table
I, Fig. 2), the effect of heat in conjunction
with BCNU differs markedly at the
different assay times, and thus contrasts
with the joint effect of heat and CTX.
Assays at both 2 and 24 h after treatment
show heat potentiation of BCNU damage
at all dose levels, but 2 h after treatment
there is only a slight downward shift of
the curve, not altering its slope. However,
at 24 h the effect is much greater, heat
markedly increases the slope of the curve,
and the potentiation at 60 mg/kg is by
about 10-fold, compared with a factor of 2
for the 2h assay. It is not clear why heat
potentiation of drug damage should be
on a different time scale for different
drugs, but evidently the balance offactors
affecting the measurement of the stem-
cell assay (detailed in the introduction)
differs according to the exact nature of
the heat potentiation, and from drug to
drug.
The nadir of stem-cell survival after
CTX has been shown to be at Day 1 after
treatment by various workers, by both
in vivo (Valeriote et al., 1968) and in vitro
assay (Brown & Carbone, 1971) and this
would perhaps support the view that the
24h assay is the more useful. The fact that
the peripheral WBC counts, being a
measure of the end-product of stem cell
killing, appear to agree more closely with
the 24h stem-cell assay than with the 2h
assay for both drugs (see Results) again
argues that the 24h stem-cell assay data
are the more relevant.
As already stated, 24 h after treatment
is the optimum time for a reliable estimate
of clonogenic tumour-cell survival, in that
all or most repair of PLD is complete, but
there has been little time for proliferation
of clonogenic surviving cells. The agree-
ment between the tumour-regrowth data
and the clonogenic assay supports the
validity ofthe 24h clonogenic assay. Hence
the comparison of 24h stem-cell survival
with 24h clonogenic tumour-cell survival
is likely to give realistic estimates of TR
for the combination ofheat with the drugs
tested. These estimates are most dis-
couraging from a therapeutic viewpoint,
as they indicate variation from no thera-
peutic gain to a considerable therapeutic
loss, according to the dose of drug (Table
IV). However, these studies only involve
combinations where drug is given at the
start of heating, and it is possible that the
time scale of heat potentiation of drug
toxicity may be substantially different for
tumour and normal tissues, thus allowing
a therapeutic advantage. Such an effect
has been shown for the combination of
waterbath heating and X-rays, using skin
desquamation as the normal-tissue end-
point (Hill & Denekamp, 1979).
It is interesting that very similar TRs
were obtained for two drugs, CTX being
very active against the RIF-l tumour
and BCNU relatively inactive against this
tumour, even at very high doses. Despite
the insensitivity of RIF-1 to BCNU, the
toxicity observed was potentiated to
about the same degree by the heat as was
that of CTX, though the data are not as
clear as those for CTX, being almost all
within one decade of killing. This led to
similar TRs, since the sensitivity of mar-
row stem cells was similar to both drugs
over the dose ranges used. It would be
interesting to investigate heat potentiation
of the BCNU effect against a BCNU-
sensitive tumour in the same strain of
mouse, which we have not yet been able
to do.
The lack of therapeutic advantage seen
from this work is perhaps all the more
discouraging from a clinical point of view
because the temperature and time for
which it is maintained (41°C for 45 min)
constitute such a mild treatment. It is
true that mice are not the ideal model
animals for whole-body hyperthermia,
being highly susceptible to heat stroke,
but it seems reasonable to assume that,
if animals do not succumb to heat stroke,
the reactions of their haemopoietic sys-
tems might be typicallymammalian. Much
higher temperatures than 4l0C are cur-
rently being tried for longer periods of
local hyperthermia in clinical studies and,
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as already mentioned, it has been sug-
gested that mild whole-body hyperthermia
(at up to 41°C) might be deliberately used
in conjunction with local heating to
reduce the problem of blood cooling. This
problem of blood cooling remains despite
the recent improvements in techniques of
localizing administered heat. Our results
suggest that any attempt to combine
agents such as CTX or BCNU with such
heating methods would be most unwise,
and thus essentially agree with the find-
ings of Rose et al. (1979). These workers
used an incubator heating method, but
unfortunately their heat doses (quoted as
> 415°C for 20 min and > 41°C for 30 min)
which resulted from accumulation of body
heat in an incubator at 387°C cannot be
compared with ours. This is because the
"temperature measurement" mice were
anaesthetized with pentobarbitone, while
the experimental mice were not. It is now
known that pentobarbitone anaesthesia
abolishes the animal's temperature-regula-
tion mechanism, so the temperature ofthe
monitored mice is unlikely to represent
that of the experimental mice, and it is
most likely that the unanaesthetized mice
at a much lower temperature.
The work presented in this paper indi-
cates that the simultaneous combination
of heat and CTX or BCNU leads to no
therapeutic gain, and under some condi-
tions to therapeutic loss, the therapeutic
ratios being estimated by comparing
tumour toxicity and marrow toxicity.
W'e wvish to tlhank Dr Peter Twentyman for many
hlelpful discussions during the course of this work.
WNre also thank Mrs Jill Shaw forcaringfor theanimals
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